ASX:SOM

SomnoMed Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume95,124 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive SOM News and Ratings via Email

Sign-up to receive the latest news and ratings for SomnoMed and its competitors with MarketBeat's FREE daily newsletter.

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.

Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: ASX
Industry: Medical Devices
Sub-Industry: N/A
Sector: Medical
Current Symbol: ASX:SOM
Previous Symbol
CUSIP: N/A
CIK: N/A
Web: somnomed.com
Phone: 61 2 9467 0400
Employees: N/A
Year Founded: N/A

Sales & Book Value

Annual Sales: $62.71 million
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: 7.61
Book Value: A$0.39 per share
Price / Book: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: N/A
Net Margins: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: 27.70
Current Ratio: 2.11
Quick Ratio: 1.81

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: -0.13

Miscellaneous

Outstanding Shares: N/A
Market Cap: N/A
Next Earnings Date: N/A
Optionable: Not Optionable

MarketRank^™

Overall MarketRank^™

0.00 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for SomnoMed.

0.0 Community Rank

Outperform Votes
SomnoMed has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
SomnoMed has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about SomnoMed and other stocks. Vote “Outperform” if you believe SOM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SOM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
SomnoMed does not currently pay a dividend.
Dividend Growth
SomnoMed does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, SomnoMed insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Growth Ratio
Due to a projected decrease in earnings for SomnoMed, their PEG ratio cannot be calculated.

See Top Rated MarketRank™ Stocks Here

SomnoMed (ASX:SOM) Frequently Asked Questions

What stocks does MarketBeat like better than SomnoMed?: Wall Street analysts have given SomnoMed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SomnoMed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.
When is SomnoMed's next earnings date?: SomnoMed is scheduled to release its next quarterly earnings announcement on Friday, October 29th 2021.
View our earnings forecast for SomnoMed.
Who are SomnoMed's key executives?: SomnoMed's management team includes the following people:
Mr. Neil Verdal-Austin, CEO, MD & Director
Mr. HervÃ© FiÃ©vet, Chief Financial Officer
Mr. Mark Harding, VP of Global Marketing
Mr. Martin Weiland, Exec. VP of Sales and Marketing - Europe
Mr. Matthew Conlon, Exec. VP Sales & Marketing - North America
Dr. Jagdeep Bijwadia, Chief Medical Officer
Mr. Terence A. Flitcroft, Company Sec. (Age 62)
Dr. Peter Spencer MBA Ph.D., MAICD, Gen. Mang. of Operations (Age 65)
Mr. Christopher Bedford, VP of Global Production and Product Devel.
Who are some of SomnoMed's key competitors?: Some companies that are related to SomnoMed include 4DMedical (4DX), Adherium (ADR), ADM Tronics Unlimited (ADMT), Allegra Orthopaedics (AMT), Analytica (ALT), AnteoTech (ADO), Anteris Technologies (AVR), Asensus Surgical (ASXC), Atomo Diagnostics (AT1), AVITA Medical (AVH), Azure Healthcare Limited (AZV.AX) (AZV), Cannabix Technologies (BLO), CleanSpace (CSX), Cochlear (COH) and Cochlear (CHEOY).
View all of SOM's competitors.
What is SomnoMed's stock symbol?: SomnoMed trades on the ASX under the ticker symbol "SOM."
How much money does SomnoMed make?: SomnoMed has a market capitalization of $0.00 and generates $62.71 million in revenue each year.
What is SomnoMed's official website?: The official website for SomnoMed is somnomed.com.
How can I contact SomnoMed?: The company can be reached via phone at 61 2 9467 0400.

This page was last updated on 10/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms

Your Ultimate Investing Toolkit

Just $1.00 for your first month.